Advertisement

Tumor Biology

, Volume 37, Issue 7, pp 8515–8528 | Cite as

Oncogenic roles and drug target of CXCR4/CXCL12 axis in lung cancer and cancer stem cell

  • Zhidong Wang
  • Jian Sun
  • Yeqian Feng
  • Xiaocai Tian
  • Bin Wang
  • Yong Zhou
Review

Abstract

Although the great progress has been made in diagnosis and therapeutic in lung cancer, it induces the most cancer death worldwide in both males and females. Chemokines, which have chemotactic abilities, contain up to 50 family members. By binding to G protein-coupled receptors (GPCR), holding seven-transmembrane domain, they function in immune cell trafficking and regulation of cell proliferation, differentiation, activation, and migration, homing under both physiologic and pathologic conditions. The alpha-chemokine receptor CXCR4 for the alpha-chemokine stromal cell-derived-factor-1 (SDF-1) is most widely expressed by tumors. In addition to human tissues of the bone marrow, liver, adrenal glands, and brain, the CXC chemokine SDF-1 or CXCL12 is also highly expressed in lung cancer tissues and is associated with lung metastasis. Lung cancer cells have the capabilities to utilize and manipulate the CXCL12/CXCR system to benefit growth and distant spread. CXCL12/CXCR4 axis is a major culprit for lung cancer and has a crucial role in lung cancer initiation and progression by activating cancer stem cell. This review provides an evaluation of CXCL12/CXCR4 as the potential therapeutic target for lung cancers; it also focuses on the synergistic effects of inhibition of CXCL12/CXCR4 axis and immunotherapy as well as chemotherapy. Together, CXCL12/CXCR4 axis can be a potential therapeutic target for lung cancers and has additive effects with immunotherapy.

Keywords

Lung cancer Cancer stem cell Chemokine CXCR4 CXCL12 Immunotherapy 

Notes

Compliance with ethical standards

Conflicts of interest

None

References

  1. 1.
    DeSantis CE, Lin CC, Mariotto AB, Siegel RL, Stein KD, et al. Cancer treatment and survivorship statistics, 2014. CA Cancer J Clin. 2014;64:252–71.PubMedGoogle Scholar
  2. 2.
    Spiro SG, Silvestri GA. One hundred years of lung cancer. Am J Respir Crit Care Med. 2005;172:523–9.PubMedGoogle Scholar
  3. 3.
    Pao W, Girard N. New driver mutations in non-small-cell lung cancer. Lancet Oncol. 2011;12:175–80.PubMedGoogle Scholar
  4. 4.
    Pao W, Hutchinson KE. Chipping away at the lung cancer genome. Nat Med. 2012;18:349–51.PubMedGoogle Scholar
  5. 5.
    Alberg AJ, Ford JG, Samet JM. Epidemiology of lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition). Chest. 2007;132:29S–55.PubMedGoogle Scholar
  6. 6.
    Siegel R, DeSantis C, Virgo K, Stein K, Mariotto A, et al. Cancer treatment and survivorship statistics, 2012. CA Cancer J Clin. 2012;62:220–41.PubMedGoogle Scholar
  7. 7.
    Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012;62:10–29.PubMedGoogle Scholar
  8. 8.
    Dela CCS, Tanoue LT, Matthay RA. Lung cancer: epidemiology, etiology, and prevention. Clin Chest Med. 2011;32:605–44.Google Scholar
  9. 9.
    Molina JR, Yang P, Cassivi SD, Schild SE, Adjei AA. Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc. 2008;83:584–94.PubMedPubMedCentralGoogle Scholar
  10. 10.
    Steliga MA, Dresler CM. Epidemiology of lung cancer: smoking, secondhand smoke, and genetics. Surg Oncol Clin N Am. 2011;20:605–18.PubMedGoogle Scholar
  11. 11.
    DeVita VT, Hellman S. Cancer: principles and practice of oncology. Lippincott Williams & Wilkins; 2005. p. 7.Google Scholar
  12. 12.
    Furuse K, Fukuoka M, Kawahara M, Nishikawa H, Takada Y, et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer. J Clin Oncol. 1999;17:2692–9.PubMedGoogle Scholar
  13. 13.
    Auperin A, Le PC, Rolland E, Curran WJ, Furuse K, et al. Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer. J Clin Oncol. 2010;28:2181–90.PubMedGoogle Scholar
  14. 14.
    Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med. 2002;346:92–8.PubMedGoogle Scholar
  15. 15.
    Surveillance E, End Results (SEER) Program. SEER-Medicare linked database 2006–2010. Bethesda: National Cancer Institute, Division of Cancer Control and Population Sciences, Applied Research Program, Health Services and Economics Branch; 2013.Google Scholar
  16. 16.
    Solomon BJ, Mok T, Kim DW, Wu YL, Nakagawa K, et al. First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med. 2014;371:2167–77.PubMedGoogle Scholar
  17. 17.
    Bezwoda WR, Lewis D, Livini N. Bone marrow involvement in anaplastic small cell lung cancer. Diagnosis, hematologic features, and prognostic implications. Cancer. 1986;58:1762–5.PubMedGoogle Scholar
  18. 18.
    Minna JD, Roth JA, Gazdar AF. Focus on lung cancer. Cancer Cell. 2002;1:49–52.PubMedGoogle Scholar
  19. 19.
    Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin. 2014;64:9–29.PubMedGoogle Scholar
  20. 20.
    Gandara DR, Lara Jr PN, Mack P, Scagliotti G. Individualizing therapy for non-small-cell lung cancer: a paradigm shift from empiric to integrated decision-making. Clin Lung Cancer. 2009;10:148–50.PubMedGoogle Scholar
  21. 21.
    Hanna N, Bunn Jr PA, Langer C, Einhorn L, Guthrie Jr T, et al. Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer. J Clin Oncol. 2006;24:2038–43.PubMedGoogle Scholar
  22. 22.
    Owonikoko TK, Behera M, Chen Z, Bhimani C, Curran WJ, et al. A systematic analysis of efficacy of second-line chemotherapy in sensitive and refractory small-cell lung cancer. J Thorac Oncol. 2012;7:866–72.PubMedPubMedCentralGoogle Scholar
  23. 23.
    Ono SJ, Nakamura T, Miyazaki D, Ohbayashi M, Dawson M, et al. Chemokines: roles in leukocyte development, trafficking, and effector function. J Allergy Clin Immunol. 2003;111:1185–99. quiz 1200.PubMedGoogle Scholar
  24. 24.
    Mukaida N, Baba T. Chemokines in tumor development and progression. Exp Cell Res. 2012;318:95–102.PubMedGoogle Scholar
  25. 25.
    Keeley EC, Mehrad B, Strieter RM. Chemokines as mediators of tumor angiogenesis and neovascularization. Exp Cell Res. 2011;317:685–90.PubMedGoogle Scholar
  26. 26.
    Gerber PA, Hippe A, Buhren BA, Muller A, Homey B. Chemokines in tumor-associated angiogenesis. Biol Chem. 2009;390:1213–23.PubMedGoogle Scholar
  27. 27.
    Zlotnik A, Yoshie O. Chemokines: a new classification system and their role in immunity. Immunity. 2000;12:121–7.PubMedGoogle Scholar
  28. 28.
    Murphy PM, Baggiolini M, Charo IF, Hebert CA, Horuk R, et al. International union of pharmacology. XXII. Nomenclature for chemokine receptors. Pharmacol Rev. 2000;52:145–76.PubMedGoogle Scholar
  29. 29.
    Zlotnik A, Burkhardt AM, Homey B. Homeostatic chemokine receptors and organ-specific metastasis. Nat Rev Immunol. 2011;11:597–606.PubMedGoogle Scholar
  30. 30.
    Wald O, Shapira OM, Izhar U. CXCR4/CXCL12 axis in non small cell lung cancer (NSCLC) pathologic roles and therapeutic potential. Theranostics. 2013;3:26–33.PubMedPubMedCentralGoogle Scholar
  31. 31.
    Mantovani A. Chemokines in neoplastic progression. Semin Cancer Biol. 2004;14:147–8.PubMedGoogle Scholar
  32. 32.
    Mantovani A, Allavena P, Sozzani S, Vecchi A, Locati M, et al. Chemokines in the recruitment and shaping of the leukocyte infiltrate of tumors. Semin Cancer Biol. 2004;14:155–60.PubMedGoogle Scholar
  33. 33.
    Muller A, Homey B, Soto H, Ge N, Catron D, et al. Involvement of chemokine receptors in breast cancer metastasis. Nature. 2001;410:50–6.PubMedGoogle Scholar
  34. 34.
    Salvucci O, Yao L, Villalba S, Sajewicz A, Pittaluga S, et al. Regulation of endothelial cell branching morphogenesis by endogenous chemokine stromal-derived factor-1. Blood. 2002;99:2703–11.PubMedGoogle Scholar
  35. 35.
    Hou KL, Hao MG, Bo JJ, Wang JH. CXCR7 in tumorigenesis and progression. Chin J Cancer. 2010;29:456–9.PubMedGoogle Scholar
  36. 36.
    Pawig L, Klasen C, Weber C, Bernhagen J, Noels H. Diversity and inter-connections in the CXCR4 chemokine receptor/ligand family: molecular perspectives. Front Immunol. 2015;6:429.PubMedPubMedCentralGoogle Scholar
  37. 37.
    Petit I, Jin D, Rafii S. The SDF-1-CXCR4 signaling pathway: a molecular hub modulating neo-angiogenesis. Trends Immunol. 2007;28:299–307.PubMedPubMedCentralGoogle Scholar
  38. 38.
    Nagasawa T, Kikutani H, Kishimoto T. Molecular cloning and structure of a pre-B-cell growth-stimulating factor. Proc Natl Acad Sci U S A. 1994;91:2305–9.PubMedPubMedCentralGoogle Scholar
  39. 39.
    Busillo JM, Benovic JL. Regulation of CXCR4 signaling. Biochim Biophys Acta. 2007;1768:952–63.PubMedGoogle Scholar
  40. 40.
    Kucia M, Reca R, Miekus K, Wanzeck J, Wojakowski W, et al. Trafficking of normal stem cells and metastasis of cancer stem cells involve similar mechanisms: pivotal role of the SDF-1-CXCR4 axis. Stem Cells. 2005;23:879–94.PubMedGoogle Scholar
  41. 41.
    Dewan MZ, Ahmed S, Iwasaki Y, Ohba K, Toi M, et al. Stromal cell-derived factor-1 and CXCR4 receptor interaction in tumor growth and metastasis of breast cancer. Biomed Pharmacother. 2006;60:273–6.PubMedGoogle Scholar
  42. 42.
    Decaillot FM, Kazmi MA, Lin Y, Ray-Saha S, Sakmar TP, et al. CXCR7/CXCR4 heterodimer constitutively recruits beta-arrestin to enhance cell migration. J Biol Chem. 2011;286:32188–97.PubMedPubMedCentralGoogle Scholar
  43. 43.
    Singh AK, Arya RK, Trivedi AK, Sanyal S, Baral R, et al. Chemokine receptor trio: CXCR3, CXCR4 and CXCR7 crosstalk via CXCL11 and CXCL12. Cytokine Growth Factor Rev. 2013;24:41–9.PubMedGoogle Scholar
  44. 44.
    Sun X, Cheng G, Hao M, Zheng J, Zhou X, et al. CXCL12 / CXCR4 / CXCR7 chemokine axis and cancer progression. Cancer Metastasis Rev. 2010;29:709–22.PubMedPubMedCentralGoogle Scholar
  45. 45.
    Cheng ZJ, Zhao J, Sun Y, Hu W, Wu YL, et al. Beta-arrestin differentially regulates the chemokine receptor CXCR4-mediated signaling and receptor internalization, and this implicates multiple interaction sites between beta-arrestin and CXCR4. J Biol Chem. 2000;275:2479–85.PubMedGoogle Scholar
  46. 46.
    Sun Y, Cheng Z, Ma L, Pei G. Beta-arrestin2 is critically involved in CXCR4-mediated chemotaxis, and this is mediated by its enhancement of p38 MAPK activation. J Biol Chem. 2002;277:49212–9.PubMedGoogle Scholar
  47. 47.
    Romain B, Hachet-Haas M, Rohr S, Brigand C, Galzi JL, et al. Hypoxia differentially regulated CXCR4 and CXCR7 signaling in colon cancer. Mol Cancer. 2014;13:58.PubMedPubMedCentralGoogle Scholar
  48. 48.
    Choe Y, Pleasure SJ. Wnt signaling regulates intermediate precursor production in the postnatal dentate gyrus by regulating CXCR4 expression. Dev Neurosci. 2012;34:502–14.PubMedGoogle Scholar
  49. 49.
    Bai R, Zhao H, Zhang X, Du S. Characterization of sonic hedgehog inhibition in gastric carcinoma cells. Oncol Lett. 2014;7:1381–4.PubMedPubMedCentralGoogle Scholar
  50. 50.
    Wang J, Cai J, Han F, Yang C, Tong Q, et al. Silencing of CXCR4 blocks progression of ovarian cancer and depresses canonical Wnt signaling pathway. Int J Gynecol Cancer. 2011;21:981–7.PubMedGoogle Scholar
  51. 51.
    Tamura M, Sato MM, Nashimoto M. Regulation of CXCL12 expression by canonical Wnt signaling in bone marrow stromal cells. Int J Biochem Cell Biol. 2011;43:760–7.PubMedGoogle Scholar
  52. 52.
    Jin Z, Zhao C, Han X, Han Y. Wnt5a promotes Ewing sarcoma cell migration through upregulating CXCR4 expression. BMC Cancer. 2012;12:480.PubMedPubMedCentralGoogle Scholar
  53. 53.
    Esencay M, Newcomb EW, Zagzag D. HGF upregulates CXCR4 expression in gliomas via NF-kappaB: implications for glioma cell migration. J Neurooncol. 2010;99:33–40.PubMedPubMedCentralGoogle Scholar
  54. 54.
    Maroni P, Bendinelli P, Matteucci E, Desiderio MA. HGF induces CXCR4 and CXCL12-mediated tumor invasion through Ets1 and NF-kappaB. Carcinogenesis. 2007;28:267–79.PubMedGoogle Scholar
  55. 55.
    Matteucci E, Ridolfi E, Maroni P, Bendinelli P, Desiderio MA. c-Src/histone deacetylase 3 interaction is crucial for hepatocyte growth factor dependent decrease of CXCR4 expression in highly invasive breast tumor cells. Mol Cancer Res. 2007;5:833–45.PubMedGoogle Scholar
  56. 56.
    Ridolfi E, Matteucci E, Maroni P, Desiderio MA. Inhibitory effect of HGF on invasiveness of aggressive MDA-MB231 breast carcinoma cells, and role of HDACs. Br J Cancer. 2008;99:1623–34.PubMedPubMedCentralGoogle Scholar
  57. 57.
    Cao Y, Karin M. NF-kappaB in mammary gland development and breast cancer. J Mammary Gland Biol Neoplasia. 2003;8:215–23.PubMedGoogle Scholar
  58. 58.
    Helbig G, Christopherson 2nd KW, Bhat-Nakshatri P, Kumar S, Kishimoto H, et al. NF-kappaB promotes breast cancer cell migration and metastasis by inducing the expression of the chemokine receptor CXCR4. J Biol Chem. 2003;278:21631–8.PubMedGoogle Scholar
  59. 59.
    Fareh M, Turchi L, Virolle V, Debruyne D, Almairac F, et al. The miR 302–367 cluster drastically affects self-renewal and infiltration properties of glioma-initiating cells through CXCR4 repression and consequent disruption of the SHH-GLI-NANOG network. Cell Death Differ. 2012;19:232–44.PubMedGoogle Scholar
  60. 60.
    Hinton CV, Avraham S, Avraham HK. Role of the CXCR4/CXCL12 signaling axis in breast cancer metastasis to the brain. Clin Exp Metastasis. 2010;27:97–105.PubMedGoogle Scholar
  61. 61.
    Peng SB, Peek V, Zhai Y, Paul DC, Lou Q, et al. Akt activation, but not extracellular signal-regulated kinase activation, is required for SDF-1alpha/CXCR4-mediated migration of epitheloid carcinoma cells. Mol Cancer Res. 2005;3:227–36.PubMedGoogle Scholar
  62. 62.
    Han Y, He T, Huang DR, Pardo CA, Ransohoff RM. TNF-alpha mediates SDF-1 alpha-induced NF-kappa B activation and cytotoxic effects in primary astrocytes. J Clin Invest. 2001;108:425–35.PubMedPubMedCentralGoogle Scholar
  63. 63.
    Vila-Coro AJ, Rodriguez-Frade JM, Martin DAA, Moreno-Ortiz MC, Martinez-A C, et al. The chemokine SDF-1alpha triggers CXCR4 receptor dimerization and activates the JAK/STAT pathway. FASEB J. 1999;13:1699–710.PubMedGoogle Scholar
  64. 64.
    Soldevila G, Licona I, Salgado A, Ramirez M, Chavez R, et al. Impaired chemokine-induced migration during T-cell development in the absence of Jak 3. Immunology. 2004;112:191–200.PubMedPubMedCentralGoogle Scholar
  65. 65.
    Kukreja P, Abdel-Mageed AB, Mondal D, Liu K, Agrawal KC. Up-regulation of CXCR4 expression in PC-3 cells by stromal-derived factor-1alpha (CXCL12) increases endothelial adhesion and transendothelial migration: role of MEK/ERK signaling pathway-dependent NF-kappaB activation. Cancer Res. 2005;65:9891–8.PubMedGoogle Scholar
  66. 66.
    Cabioglu N, Summy J, Miller C, Parikh NU, Sahin AA, et al. CXCL-12/stromal cell-derived factor-1alpha transactivates HER2-neu in breast cancer cells by a novel pathway involving Src kinase activation. Cancer Res. 2005;65:6493–7.PubMedGoogle Scholar
  67. 67.
    Chinni SR, Yamamoto H, Dong Z, Sabbota A, Bonfil RD, et al. CXCL12/CXCR4 transactivates HER2 in lipid rafts of prostate cancer cells and promotes growth of metastatic deposits in bone. Mol Cancer Res. 2008;6:446–57.PubMedGoogle Scholar
  68. 68.
    Porcile C, Bajetto A, Barbieri F, Barbero S, Bonavia R, et al. Stromal cell-derived factor-1alpha (SDF-1alpha/CXCL12) stimulates ovarian cancer cell growth through the EGF receptor transactivation. Exp Cell Res. 2005;308:241–53.PubMedGoogle Scholar
  69. 69.
    Al ZAA, Al OBF, Yang L, Yang C, Hui Y, et al. Concomitant overexpression of EGFR and CXCR4 is associated with worse prognosis in a new molecular subtype of non-small cell lung cancer. Oncol Rep. 2013;29:1524–32.Google Scholar
  70. 70.
    Tsai MF, Chang TH, Wu SG, Yang HY, Hsu YC, et al. EGFR-L858R mutant enhances lung adenocarcinoma cell invasive ability and promotes malignant pleural effusion formation through activation of the CXCL12-CXCR4 pathway. Sci Rep. 2015;5:13574.PubMedPubMedCentralGoogle Scholar
  71. 71.
    Marchese A, Raiborg C, Santini F, Keen JH, Stenmark H, et al. The E3 ubiquitin ligase AIP4 mediates ubiquitination and sorting of the G protein-coupled receptor CXCR4. Dev Cell. 2003;5:709–22.PubMedGoogle Scholar
  72. 72.
    Rahimi M, George J, Tang C. EGFR variant-mediated invasion by enhanced CXCR4 expression through transcriptional and post-translational mechanisms. Int J Cancer. 2010;126:1850–60.PubMedPubMedCentralGoogle Scholar
  73. 73.
    Begon DY, Delacroix L, Vernimmen D, Jackers P, Winkler R. Yin Yang 1 cooperates with activator protein 2 to stimulate ERBB2 gene expression in mammary cancer cells. J Biol Chem. 2005;280:24428–34.PubMedGoogle Scholar
  74. 74.
    Lee BC, Lee TH, Zagozdzon R, Avraham S, Usheva A, et al. Carboxyl-terminal Src kinase homologous kinase negatively regulates the chemokine receptor CXCR4 through YY1 and impairs CXCR4/CXCL12 (SDF-1alpha)-mediated breast cancer cell migration. Cancer Res. 2005;65:2840–5.PubMedGoogle Scholar
  75. 75.
    Kim HC, Choi KC, Choi HK, Kang HB, Kim MJ, et al. HDAC3 selectively represses CREB3-mediated transcription and migration of metastatic breast cancer cells. Cell Mol Life Sci. 2010;67:3499–510.PubMedGoogle Scholar
  76. 76.
    Uchida D, Onoue T, Begum NM, Kuribayashi N, Tomizuka Y, et al. Vesnarinone downregulates CXCR4 expression via upregulation of Kruppel-like factor 2 in oral cancer cells. Mol Cancer. 2009;8:62.PubMedPubMedCentralGoogle Scholar
  77. 77.
    Luker KE, Luker GD. Functions of CXCL12 and CXCR4 in breast cancer. Cancer Lett. 2006;238:30–41.PubMedGoogle Scholar
  78. 78.
    Li YM, Pan Y, Wei Y, Cheng X, Zhou BP, et al. Upregulation of CXCR4 is essential for HER2-mediated tumor metastasis. Cancer Cell. 2004;6:459–69.PubMedGoogle Scholar
  79. 79.
    Liang Z, Brooks J, Willard M, Liang K, Yoon Y, et al. CXCR4/CXCL12 axis promotes VEGF-mediated tumor angiogenesis through Akt signaling pathway. Biochem Biophys Res Commun. 2007;359:716–22.PubMedPubMedCentralGoogle Scholar
  80. 80.
    Miyoshi K, Kohashi K, Fushimi F, Yamamoto H, Kishimoto J, et al. Close correlation between CXCR4 and VEGF expression and frequent CXCR7 expression in rhabdomyosarcoma. Hum Pathol. 2014;45:1900–9.PubMedGoogle Scholar
  81. 81.
    Seong H, Ryu J, Jeong JY, Chung IY, Han YS, et al. Resveratrol suppresses vascular endothelial growth factor secretion via inhibition of CXC-chemokine receptor 4 expression in ARPE-19 cells. Mol Med Rep. 2015;12:1479–84.PubMedGoogle Scholar
  82. 82.
    Balkwill F. Cancer and the chemokine network. Nat Rev Cancer. 2004;4:540–50.PubMedGoogle Scholar
  83. 83.
    Balkwill FR. The chemokine system and cancer. J Pathol. 2012;226:148–57.PubMedGoogle Scholar
  84. 84.
    Gangadhar T, Nandi S, Salgia R. The role of chemokine receptor CXCR4 in lung cancer. Cancer Biol Ther. 2010;9:409–16.PubMedGoogle Scholar
  85. 85.
    Xu C, Zhao H, Chen H, Yao Q. CXCR4 in breast cancer: oncogenic role and therapeutic targeting. Drug Des Devel Ther. 2015;9:4953–64.PubMedPubMedCentralGoogle Scholar
  86. 86.
    Zhao H, Guo L, Zhao J, Weng H, Zhao B. CXCR4 over-expression and survival in cancer: a system review and meta-analysis. Oncotarget. 2015;6:5022–40.PubMedGoogle Scholar
  87. 87.
    Zhou XM, He L, Hou G, Jiang B, Wang YH, et al. Clinicopathological significance of CXCR4 in non-small cell lung cancer. Drug Des Devel Ther. 2015;9:1349–58.PubMedPubMedCentralGoogle Scholar
  88. 88.
    Ghosh MC, Makena PS, Gorantla V, Sinclair SE, Waters CM. CXCR4 regulates migration of lung alveolar epithelial cells through activation of Rac1 and matrix metalloproteinase-2. Am J Physiol Lung Cell Mol Physiol. 2012;302:L846–56.PubMedPubMedCentralGoogle Scholar
  89. 89.
    Huang YC, Hsiao YC, Chen YJ, Wei YY, Lai TH, et al. Stromal cell-derived factor-1 enhances motility and integrin up-regulation through CXCR4, ERK and NF-kappaB-dependent pathway in human lung cancer cells. Biochem Pharmacol. 2007;74:1702–12.PubMedGoogle Scholar
  90. 90.
    Onoue T, Uchida D, Begum NM, Tomizuka Y, Yoshida H, et al. Epithelial-mesenchymal transition induced by the stromal cell-derived factor-1/CXCR4 system in oral squamous cell carcinoma cells. Int J Oncol. 2006;29:1133–8.PubMedGoogle Scholar
  91. 91.
    Bertolini G, D’Amico L, Moro M, Landoni E, Perego P, et al. Microenvironment-modulated metastatic CD133+/CXCR4+/EpCAM- lung cancer-initiating cells sustain tumor dissemination and correlate with poor prognosis. Cancer Res. 2015;75:3636–49.PubMedGoogle Scholar
  92. 92.
    Wang M, Chen GY, Song HT, Hong X, Yang ZY, et al. Significance of CXCR4, phosphorylated STAT3 and VEGF-A expression in resected non-small cell lung cancer. Exp Ther Med. 2011;2:517–22.PubMedPubMedCentralGoogle Scholar
  93. 93.
    Cai X, Chen Z, Pan X, Xia L, Chen P, et al. Inhibition of angiogenesis, fibrosis and thrombosis by tetramethylpyrazine: mechanisms contributing to the SDF-1/CXCR4 axis. PLoS One. 2014;9, e88176.PubMedPubMedCentralGoogle Scholar
  94. 94.
    Su L, Zhang J, Xu H, Wang Y, Chu Y, et al. Differential expression of CXCR4 is associated with the metastatic potential of human non-small cell lung cancer cells. Clin Cancer Res. 2005;11:8273–80.PubMedGoogle Scholar
  95. 95.
    Wang L, Wang Z, Liu X, Liu F. High-level C-X-C chemokine receptor type 4 expression correlates with brain-specific metastasis following complete resection of non-small cell lung cancer. Oncol Lett. 2014;7:1871–6.PubMedPubMedCentralGoogle Scholar
  96. 96.
    Choi YH, Burdick MD, Strieter BA, Mehrad B, Strieter RM. CXCR4, but not CXCR7, discriminates metastatic behavior in non-small cell lung cancer cells. Mol Cancer Res. 2014;12:38–47.PubMedGoogle Scholar
  97. 97.
    Wagner PL, Hyjek E, Vazquez MF, Meherally D, Liu YF, et al. CXCL12 and CXCR4 in adenocarcinoma of the lung: association with metastasis and survival. J Thorac Cardiovasc Surg. 2009;137:615–21.PubMedGoogle Scholar
  98. 98.
    Singla AK, Downey CM, Bebb GD, Jirik FR. Characterization of a murine model of metastatic human non-small cell lung cancer and effect of CXCR4 inhibition on the growth of metastases. Oncoscience. 2015;2:263–71.PubMedPubMedCentralGoogle Scholar
  99. 99.
    Valastyan S, Weinberg RA. Tumor metastasis: molecular insights and evolving paradigms. Cell. 2011;147:275–92.PubMedPubMedCentralGoogle Scholar
  100. 100.
    Polyak K, Haviv I, Campbell IG. Co-evolution of tumor cells and their microenvironment. Trends Genet. 2009;25:30–8.PubMedGoogle Scholar
  101. 101.
    Pietras K, Ostman A. Hallmarks of cancer: interactions with the tumor stroma. Exp Cell Res. 2010;316:1324–31.PubMedGoogle Scholar
  102. 102.
    Panneerselvam J, Jin J, Shanker M, Lauderdale J, Bates J, et al. IL-24 inhibits lung cancer cell migration and invasion by disrupting the SDF-1/CXCR4 signaling axis. PLoS One. 2015;10:e0122439.PubMedPubMedCentralGoogle Scholar
  103. 103.
    Quint LE, Tummala S, Brisson LJ, Francis IR, Krupnick AS, et al. Distribution of distant metastases from newly diagnosed non-small cell lung cancer. Ann Thorac Surg. 1996;62:246–50.PubMedGoogle Scholar
  104. 104.
    Chambers AF, Groom AC, MacDonald IC. Dissemination and growth of cancer cells in metastatic sites. Nat Rev Cancer. 2002;2:563–72.PubMedGoogle Scholar
  105. 105.
    Phillips RJ, Burdick MD, Lutz M, Belperio JA, Keane MP, et al. The stromal derived factor-1/CXCL12-CXC chemokine receptor 4 biological axis in non-small cell lung cancer metastases. Am J Respir Crit Care Med. 2003;167:1676–86.PubMedGoogle Scholar
  106. 106.
    Suzuki M, Mohamed S, Nakajima T, Kubo R, Tian L, et al. Aberrant methylation of CXCL12 in non-small cell lung cancer is associated with an unfavorable prognosis. Int J Oncol. 2008;33:113–9.PubMedGoogle Scholar
  107. 107.
    Zhi Y, Chen J, Zhang S, Chang X, Ma J, et al. Down-regulation of CXCL12 by DNA hypermethylation and its involvement in gastric cancer metastatic progression. Dig Dis Sci. 2012;57:650–9.PubMedGoogle Scholar
  108. 108.
    Fridrichova I, Smolkova B, Kajabova V, Zmetakova I, Krivulcik T, et al. CXCL12 and ADAM23 hypermethylation are associated with advanced breast cancers. Transl Res. 2015;165:717–30.PubMedGoogle Scholar
  109. 109.
    Zmetakova I, Danihel L, Smolkova B, Mego M, Kajabova V, et al. Evaluation of protein expression and DNA methylation profiles detected by pyrosequencing in invasive breast cancer. Neoplasma. 2013;60:635–46.PubMedGoogle Scholar
  110. 110.
    Wald O, Izhar U, Amir G, Avniel S, Bar-Shavit Y, et al. CD4+CXCR4highCD69+ T cells accumulate in lung adenocarcinoma. J Immunol. 2006;177:6983–90.PubMedGoogle Scholar
  111. 111.
    Belperio JA, Phillips RJ, Burdick MD, Lutz M, Keane M, et al. The SDF-1/CXCL 12/CXCR4 biological axis in non-small cell lung cancer metastases. Chest. 2004;125:156S.PubMedGoogle Scholar
  112. 112.
    Paratore S, Banna GL, D’Arrigo M, Saita S, Iemmolo R, et al. CXCR4 and CXCL12 immunoreactivities differentiate primary non-small-cell lung cancer with or without brain metastases. Cancer Biomark. 2011;10:79–89.PubMedGoogle Scholar
  113. 113.
    Reckamp KL, Figlin RA, Burdick MD, Dubinett SM, Elashoff RM, et al. CXCR4 expression on circulating pan-cytokeratin positive cells is associated with survival in patients with advanced non-small cell lung cancer. BMC Cancer. 2009;9:213.PubMedPubMedCentralGoogle Scholar
  114. 114.
    Zhang C, Li J, Han Y, Jiang J. A meta-analysis for CXCR4 as a prognostic marker and potential drug target in non-small cell lung cancer. Drug Des Devel Ther. 2015;9:3267–78.PubMedPubMedCentralGoogle Scholar
  115. 115.
    Otsuka S, Klimowicz AC, Kopciuk K, Petrillo SK, Konno M, et al. CXCR4 overexpression is associated with poor outcome in females diagnosed with stage IV non-small cell lung cancer. J Thorac Oncol. 2011;6:1169–78.PubMedGoogle Scholar
  116. 116.
    Spano JP, Andre F, Morat L, Sabatier L, Besse B, et al. Chemokine receptor CXCR4 and early-stage non-small cell lung cancer: pattern of expression and correlation with outcome. Ann Oncol. 2004;15:613–7.PubMedGoogle Scholar
  117. 117.
    Ponomaryov T, Peled A, Petit I, Taichman RS, Habler L, et al. Induction of the chemokine stromal-derived factor-1 following DNA damage improves human stem cell function. J Clin Invest. 2000;106:1331–9.PubMedPubMedCentralGoogle Scholar
  118. 118.
    Burger M, Glodek A, Hartmann T, Schmitt-Graff A, Silberstein LE, et al. Functional expression of CXCR4 (CD184) on small-cell lung cancer cells mediates migration, integrin activation, and adhesion to stromal cells. Oncogene. 2003;22:8093–101.PubMedGoogle Scholar
  119. 119.
    Hartmann TN, Burger JA, Glodek A, Fujii N, Burger M. CXCR4 chemokine receptor and integrin signaling co-operate in mediating adhesion and chemoresistance in small cell lung cancer (SCLC) cells. Oncogene. 2005;24:4462–71.PubMedGoogle Scholar
  120. 120.
    Pfeiffer M, Hartmann TN, Leick M, Catusse J, Schmitt-Graeff A, et al. Alternative implication of CXCR4 in JAK2/STAT3 activation in small cell lung cancer. Br J Cancer. 2009;100:1949–56.PubMedPubMedCentralGoogle Scholar
  121. 121.
    Otani Y, Kijima T, Kohmo S, Oishi S, Minami T, et al. Suppression of metastases of small cell lung cancer cells in mice by a peptidic CXCR4 inhibitor TF14016. FEBS Lett. 2012;586:3639–44.PubMedGoogle Scholar
  122. 122.
    Pang LY, Argyle DJ. Using naturally occurring tumours in dogs and cats to study telomerase and cancer stem cell biology. Biochim Biophys Acta. 2009;1792:380–91.PubMedGoogle Scholar
  123. 123.
    Kakarala M, Wicha MS. Implications of the cancer stem-cell hypothesis for breast cancer prevention and therapy. J Clin Oncol. 2008;26:2813–20.PubMedPubMedCentralGoogle Scholar
  124. 124.
    Wang J, Li ZH, White J, Zhang LB. Lung cancer stem cells and implications for future therapeutics. Cell Biochem Biophys. 2014;69:389–98.PubMedGoogle Scholar
  125. 125.
    Alamgeer M, Peacock CD, Matsui W, Ganju V, Watkins DN. Cancer stem cells in lung cancer: evidence and controversies. Respirology. 2013;18:757–64.PubMedPubMedCentralGoogle Scholar
  126. 126.
    O’Flaherty JD, Barr M, Fennell D, Richard D, Reynolds J, et al. The cancer stem-cell hypothesis: its emerging role in lung cancer biology and its relevance for future therapy. J Thorac Oncol. 2012;7:1880–90.PubMedGoogle Scholar
  127. 127.
    Clarke MF. Self-renewal and solid-tumor stem cells. Biol Blood Marrow Transplant. 2005;11:14–6.PubMedGoogle Scholar
  128. 128.
    Clevers H. The cancer stem cell: premises, promises and challenges. Nat Med. 2011;17:313–9.PubMedGoogle Scholar
  129. 129.
    Yan Y, Zuo X, Wei D. Concise review: emerging role of CD44 in cancer stem cells: a promising biomarker and therapeutic target. Stem Cells Transl Med. 2015;4:1033–43.PubMedPubMedCentralGoogle Scholar
  130. 130.
    Bourguignon LY, Shiina M, Li JJ. Hyaluronan-CD44 interaction promotes oncogenic signaling, microRNA functions, chemoresistance, and radiation resistance in cancer stem cells leading to tumor progression. Adv Cancer Res. 2014;123:255–75.PubMedGoogle Scholar
  131. 131.
    Williams K, Motiani K, Giridhar PV, Kasper S. CD44 integrates signaling in normal stem cell, cancer stem cell and (pre)metastatic niches. Exp Biol Med. 2013;238:324–38.Google Scholar
  132. 132.
    Qu H, Li R, Liu Z, Zhang J, Luo R. Prognostic value of cancer stem cell marker CD133 expression in non-small cell lung cancer: a systematic review. Int J Clin Exp Pathol. 2013;6:2644–50.PubMedPubMedCentralGoogle Scholar
  133. 133.
    Grosse-Gehling P, Fargeas CA, Dittfeld C, Garbe Y, Alison MR, et al. CD133 as a biomarker for putative cancer stem cells in solid tumours: limitations, problems and challenges. J Pathol. 2013;229:355–78.PubMedGoogle Scholar
  134. 134.
    Gorelik E, Lokshin A, Levina V. Lung cancer stem cells as a target for therapy. Anti Cancer Agents Med Chem. 2010;10:164–71.Google Scholar
  135. 135.
    Lennartsson J, Ronnstrand L. Stem cell factor receptor/c-Kit: from basic science to clinical implications. Physiol Rev. 2012;92:1619–49.PubMedGoogle Scholar
  136. 136.
    Kubo T, Takigawa N, Osawa M, Harada D, Ninomiya T, et al. Subpopulation of small-cell lung cancer cells expressing CD133 and CD87 show resistance to chemotherapy. Cancer Sci. 2013;104:78–84.PubMedGoogle Scholar
  137. 137.
    Yang Y, Fan Y, Qi Y, Liu D, Wu K, et al. Side population cells separated from A549 lung cancer cell line possess cancer stem cell-like properties and inhibition of autophagy potentiates the cytotoxic effect of cisplatin. Oncol Rep. 2015;34:929–35.PubMedGoogle Scholar
  138. 138.
    Singh S, Trevino J, Bora-Singhal N, Coppola D, Haura E, et al. EGFR/Src/Akt signaling modulates Sox2 expression and self-renewal of stem-like side-population cells in non-small cell lung cancer. Mol Cancer. 2012;11:73.PubMedPubMedCentralGoogle Scholar
  139. 139.
    Salcido CD, Larochelle A, Taylor BJ, Dunbar CE, Varticovski L. Molecular characterisation of side population cells with cancer stem cell-like characteristics in small-cell lung cancer. Br J Cancer. 2010;102:1636–44.PubMedPubMedCentralGoogle Scholar
  140. 140.
    Sullivan JP, Spinola M, Dodge M, Raso MG, Behrens C, et al. Aldehyde dehydrogenase activity selects for lung adenocarcinoma stem cells dependent on notch signaling. Cancer Res. 2010;70:9937–48.PubMedPubMedCentralGoogle Scholar
  141. 141.
    Huang CP, Tsai MF, Chang TH, Tang WC, Chen SY, et al. ALDH-positive lung cancer stem cells confer resistance to epidermal growth factor receptor tyrosine kinase inhibitors. Cancer Lett. 2013;328:144–51.PubMedGoogle Scholar
  142. 142.
    Yagui-Beltran A, Jablons DM. A translational approach to lung cancer research: from EGFRs to Wnt and cancer stem cells. Ann Thorac Cardiovasc Surg. 2009;15:213–20.PubMedPubMedCentralGoogle Scholar
  143. 143.
    Chang YW, Su YJ, Hsiao M, Wei KC, Lin WH, et al. Diverse targets of beta-catenin during the epithelial-mesenchymal transition define cancer stem cells and predict disease relapse. Cancer Res. 2015;75:3398–410.PubMedGoogle Scholar
  144. 144.
    Zhang S, Wang Y, Mao JH, Hsieh D, Kim IJ, et al. Inhibition of CK2alpha down-regulates Hedgehog/Gli signaling leading to a reduction of a stem-like side population in human lung cancer cells. PLoS One. 2012;7:e38996.PubMedPubMedCentralGoogle Scholar
  145. 145.
    Justilien V, Walsh MP, Ali SA, Thompson EA, Murray NR, et al. The PRKCI and SOX2 oncogenes are coamplified and cooperate to activate Hedgehog signaling in lung squamous cell carcinoma. Cancer Cell. 2014;25:139–51.PubMedPubMedCentralGoogle Scholar
  146. 146.
    Yen WC, Fischer MM, Axelrod F, Bond C, Cain J, et al. Targeting Notch signaling with a Notch2/Notch3 antagonist (tarextumab) inhibits tumor growth and decreases tumor-initiating cell frequency. Clin Cancer Res. 2015;21:2084–95.PubMedGoogle Scholar
  147. 147.
    Hassan KA, Wang L, Korkaya H, Chen G, Maillard I, et al. Notch pathway activity identifies cells with cancer stem cell-like properties and correlates with worse survival in lung adenocarcinoma. Clin Cancer Res. 2013;19:1972–80.PubMedPubMedCentralGoogle Scholar
  148. 148.
    Lee SO, Yang X, Duan S, Tsai Y, Strojny LR et al (2015) IL-6 promotes growth and epithelial-mesenchymal transition of CD133+ cells of non-small cell lung cancer. Oncotarget. 12.Google Scholar
  149. 149.
    Malanga D, De MC, Guerriero I, Colelli F, Rinaldo N, et al. The Akt1/IL-6/STAT3 pathway regulates growth of lung tumor initiating cells. Oncotarget. 2015;6:42667–86.PubMedPubMedCentralGoogle Scholar
  150. 150.
    Lu C, Huang T, Chen W, Lu H. GnRH participates in the self-renewal of A549-derived lung cancer stem-like cells through upregulation of the JNK signaling pathway. Oncol Rep. 2015;34:244–50.PubMedGoogle Scholar
  151. 151.
    Song W, Ma Y, Wang J, Brantley-Sieders D, Chen J. JNK signaling mediates EPHA2-dependent tumor cell proliferation, motility, and cancer stem cell-like properties in non-small cell lung cancer. Cancer Res. 2014;74:2444–54.PubMedPubMedCentralGoogle Scholar
  152. 152.
    Nian WQ, Chen FL, Ao XJ, Chen ZT. CXCR4 positive cells from Lewis lung carcinoma cell line have cancer metastatic stem cell characteristics. Mol Cell Biochem. 2011;355:241–8.PubMedGoogle Scholar
  153. 153.
    Larzabal L, El-Nikhely N, Redrado M, Seeger W, Savai R, et al. Differential effects of drugs targeting cancer stem cell (CSC) and non-CSC populations on lung primary tumors and metastasis. PLoS One. 2013;8:e79798.PubMedPubMedCentralGoogle Scholar
  154. 154.
    Moro M, Bertolini G, Pastorino U, Roz L, Sozzi G. Combination treatment with all-trans retinoic acid prevents cisplatin-induced enrichment of CD133+ tumor-initiating cells and reveals heterogeneity of cancer stem cell compartment in lung cancer. J Thorac Oncol. 2015;10:1027–36.PubMedPubMedCentralGoogle Scholar
  155. 155.
    Peled A, Wald O, Burger J. Development of novel CXCR4-based therapeutics. Expert Opin Investig Drugs. 2012;21:341–53.PubMedGoogle Scholar
  156. 156.
    Burger JA, Stewart DJ, Wald O, Peled A. Potential of CXCR4 antagonists for the treatment of metastatic lung cancer. Expert Rev Anticancer Ther. 2011;11:621–30.PubMedGoogle Scholar
  157. 157.
    Burger JA, Kipps TJ. CXCR4: a key receptor in the crosstalk between tumor cells and their microenvironment. Blood. 2006;107:1761–7.PubMedGoogle Scholar
  158. 158.
    Burger JA, Peled A. CXCR4 antagonists: targeting the microenvironment in leukemia and other cancers. Leukemia. 2009;23:43–52.PubMedGoogle Scholar
  159. 159.
    Jung MJ, Rho JK, Kim YM, Jung JE, Jin YB, et al. Upregulation of CXCR4 is functionally crucial for maintenance of stemness in drug-resistant non-small cell lung cancer cells. Oncogene. 2013;32:209–21.PubMedGoogle Scholar
  160. 160.
    Bertolini G, Roz L, Perego P, Tortoreto M, Fontanella E, et al. Highly tumorigenic lung cancer CD133+ cells display stem-like features and are spared by cisplatin treatment. Proc Natl Acad Sci U S A. 2009;106:16281–6.PubMedPubMedCentralGoogle Scholar
  161. 161.
    Lundin A, Driscoll B. Lung cancer stem cells: progress and prospects. Cancer Lett. 2013;338:89–93.PubMedGoogle Scholar
  162. 162.
    Tamamura H, Hori A, Kanzaki N, Hiramatsu K, Mizumoto M, et al. T140 analogs as CXCR4 antagonists identified as anti-metastatic agents in the treatment of breast cancer. FEBS Lett. 2003;550:79–83.PubMedGoogle Scholar
  163. 163.
    Fahham D, Weiss ID, Abraham M, Beider K, Hanna W, et al. In vitro and in vivo therapeutic efficacy of CXCR4 antagonist BKT140 against human non-small cell lung cancer. J Thorac Cardiovasc Surg. 2012;144:1167–1175 e1161.PubMedGoogle Scholar
  164. 164.
    de Nigris F, Schiano C, Infante T, Napoli C. CXCR4 inhibitors: tumor vasculature and therapeutic challenges. Recent Pat Anticancer Drug Discov. 2012;7:251–64.PubMedGoogle Scholar
  165. 165.
    Tamamura H, Hiramatsu K, Ueda S, Wang Z, Kusano S, et al. Stereoselective synthesis of [L-Arg-L/D-3-(2-naphthyl)alanine]-type (E)-alkene dipeptide isosteres and its application to the synthesis and biological evaluation of pseudopeptide analogues of the CXCR4 antagonist FC131. J Med Chem. 2005;48:380–91.PubMedGoogle Scholar
  166. 166.
    Yoshikawa Y, Kobayashi K, Oishi S, Fujii N, Furuya T. Molecular modeling study of cyclic pentapeptide CXCR4 antagonists: new insight into CXCR4-FC131 interactions. Bioorg Med Chem Lett. 2012;22:2146–50.PubMedGoogle Scholar
  167. 167.
    De CE. The AMD3100 story: the path to the discovery of a stem cell mobilizer (Mozobil). Biochem Pharmacol. 2009;77:1655–64.Google Scholar
  168. 168.
    DiPersio JF, Stadtmauer EA, Nademanee A, Micallef IN, Stiff PJ, et al. Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma. Blood. 2009;113:5720–6.PubMedGoogle Scholar
  169. 169.
    DiPersio JF, Uy GL, Yasothan U, Kirkpatrick P. Plerixafor. Nat Rev Drug Discov. 2009;8:105–6.PubMedGoogle Scholar
  170. 170.
    Stone ND, Dunaway SB, Flexner C, Tierney C, Calandra GB, et al. Multiple-dose escalation study of the safety, pharmacokinetics, and biologic activity of oral AMD070, a selective CXCR4 receptor inhibitor, in human subjects. Antimicrob Agents Chemother. 2007;51:2351–8.PubMedPubMedCentralGoogle Scholar
  171. 171.
    Nyunt MM, Becker S, MacFarland RT, Chee P, Scarborough R, et al. Pharmacokinetic effect of AMD070, an Oral CXCR4 antagonist, on CYP3A4 and CYP2D6 substrates midazolam and dextromethorphan in healthy volunteers. J Acquir Immune Defic Syndr. 2008;47:559–65.PubMedGoogle Scholar
  172. 172.
    O’Boyle G, Swidenbank I, Marshall H, Barker CE, Armstrong J, et al. Inhibition of CXCR4-CXCL12 chemotaxis in melanoma by AMD11070. Br J Cancer. 2013;108:1634–40.PubMedPubMedCentralGoogle Scholar
  173. 173.
    Liang Z, Zhan W, Zhu A, Yoon Y, Lin S, et al. Development of a unique small molecule modulator of CXCR4. PLoS One. 2012;7:e34038.PubMedPubMedCentralGoogle Scholar
  174. 174.
    Planesas JM, Perez-Nueno VI, Borrell JI, Teixido J. Studying the binding interactions of allosteric agonists and antagonists of the CXCR4 receptor. J Mol Graph Model. 2015;60:1–14.PubMedGoogle Scholar
  175. 175.
    Jenkinson S, Thomson M, McCoy D, Edelstein M, Danehower S, et al. Blockade of X4-tropic HIV-1 cellular entry by GSK812397, a potent noncompetitive CXCR4 receptor antagonist. Antimicrob Agents Chemother. 2010;54:817–24.PubMedGoogle Scholar
  176. 176.
    Murakami T, Kumakura S, Yamazaki T, Tanaka R, Hamatake M, et al. The novel CXCR4 antagonist KRH-3955 is an orally bioavailable and extremely potent inhibitor of human immunodeficiency virus type 1 infection: comparative studies with AMD3100. Antimicrob Agents Chemother. 2009;53:2940–8.PubMedPubMedCentralGoogle Scholar
  177. 177.
    Iwanaga T, Iwasaki Y, Ohashi M, Ohinata R, Takahashi K, et al. Inhibitory effect of CXCR4 blockers on a CXCR4-expressing gastric cancer cell line in nude mice. Gan To Kagaku Ryoho. 2012;39:1788–90.PubMedGoogle Scholar
  178. 178.
    Kuhne MR, Mulvey T, Belanger B, Chen S, Pan C, et al. BMS-936564/MDX-1338: a fully human anti-CXCR4 antibody induces apoptosis in vitro and shows antitumor activity in vivo in hematologic malignancies. Clin Cancer Res. 2013;19:357–66.PubMedGoogle Scholar
  179. 179.
    Gil M, Seshadri M, Komorowski MP, Abrams SI, Kozbor D. Targeting CXCL12/CXCR4 signaling with oncolytic virotherapy disrupts tumor vasculature and inhibits breast cancer metastases. Proc Natl Acad Sci U S A. 2013;110:E1291–300.PubMedPubMedCentralGoogle Scholar
  180. 180.
    Drenckhan A, Kurschat N, Dohrmann T, Raabe N, Koenig AM, et al. Effective inhibition of metastases and primary tumor growth with CTCE-9908 in esophageal cancer. J Surg Res. 2013;182:250–6.PubMedGoogle Scholar
  181. 181.
    Koga C, Kobayashi S, Nagano H, Tomimaru Y, Hama N, et al. Reprogramming using microRNA-302 improves drug sensitivity in hepatocellular carcinoma cells. Ann Surg Oncol. 2014;21 Suppl 4:S591–600.PubMedGoogle Scholar
  182. 182.
    Liang Z, Wu T, Lou H, Yu X, Taichman RS, et al. Inhibition of breast cancer metastasis by selective synthetic polypeptide against CXCR4. Cancer Res. 2004;64:4302–8.PubMedGoogle Scholar
  183. 183.
    Wald O, Izhar U, Amir G, Kirshberg S, Shlomai Z, et al. Interaction between neoplastic cells and cancer-associated fibroblasts through the CXCL12/CXCR4 axis: role in non-small cell lung cancer tumor proliferation. J Thorac Cardiovasc Surg. 2011;141:1503–12.PubMedGoogle Scholar
  184. 184.
    Zhan W, Liang Z, Zhu A, Kurtkaya S, Shim H, et al. Discovery of small molecule CXCR4 antagonists. J Med Chem. 2007;50:5655–64.PubMedGoogle Scholar
  185. 185.
    Dorsam RT, Gutkind JS. G-protein-coupled receptors and cancer. Nat Rev Cancer. 2007;7:79–94.PubMedGoogle Scholar
  186. 186.
    Rasheed ZA, Kowalski J, Smith BD, Matsui W. Concise review: emerging concepts in clinical targeting of cancer stem cells. Stem Cells. 2011;29:883–7.PubMedPubMedCentralGoogle Scholar
  187. 187.
    De CE. The bicyclam AMD3100 story. Nat Rev Drug Discov. 2003;2:581–7.Google Scholar
  188. 188.
    Donzella GA, Schols D, Lin SW, Este JA, Nagashima KA, et al. AMD3100, a small molecule inhibitor of HIV-1 entry via the CXCR4 co-receptor. Nat Med. 1998;4:72–7.PubMedGoogle Scholar
  189. 189.
    Pusic I, DiPersio JF. Update on clinical experience with AMD3100, an SDF-1/CXCL12-CXCR4 inhibitor, in mobilization of hematopoietic stem and progenitor cells. Curr Opin Hematol. 2010;17:319–26.PubMedGoogle Scholar
  190. 190.
    Muralidharan R, Panneerselvam J, Chen A, Zhao YD, Munshi A, et al. HuR-targeted nanotherapy in combination with AMD3100 suppresses CXCR4 expression, cell growth, migration and invasion in lung cancer. Cancer Gene Ther. 2015;22:581–90.PubMedPubMedCentralGoogle Scholar
  191. 191.
    Targeting chemokines and chemokine receptors with antibodies. Drug Discov Today Technol. 2012;9:e227–314.Google Scholar
  192. 192.
    Hassan S, Buchanan M, Jahan K, Aguilar-Mahecha A, Gaboury L, et al. CXCR4 peptide antagonist inhibits primary breast tumor growth, metastasis and enhances the efficacy of anti-VEGF treatment or docetaxel in a transgenic mouse model. Int J Cancer. 2011;129:225–32.PubMedGoogle Scholar
  193. 193.
    Liang Z, Bian X, Shim H. Inhibition of breast cancer metastasis with microRNA-302a by downregulation of CXCR4 expression. Breast Cancer Res Treat. 2014;146:535–42.PubMedPubMedCentralGoogle Scholar
  194. 194.
    Yu T, Liu K, Wu Y, Fan J, Chen J, et al. MicroRNA-9 inhibits the proliferation of oral squamous cell carcinoma cells by suppressing expression of CXCR4 via the Wnt/beta-catenin signaling pathway. Oncogene. 2014;33:5017–27.PubMedGoogle Scholar
  195. 195.
    Labbaye C, Spinello I, Quaranta MT, Pelosi E, Pasquini L, et al. A three-step pathway comprising PLZF/miR-146a/CXCR4 controls megakaryopoiesis. Nat Cell Biol. 2008;10:788–801.PubMedGoogle Scholar
  196. 196.
    Liang Z, Wu H, Reddy S, Zhu A, Wang S, et al. Blockade of invasion and metastasis of breast cancer cells via targeting CXCR4 with an artificial microRNA. Biochem Biophys Res Commun. 2007;363:542–6.PubMedGoogle Scholar
  197. 197.
    Chen D, Huang J, Zhang K, Pan B, Chen J, et al. MicroRNA-451 induces epithelial-mesenchymal transition in docetaxel-resistant lung adenocarcinoma cells by targeting proto-oncogene c-Myc. Eur J Cancer. 2014;50:3050–67.PubMedGoogle Scholar
  198. 198.
    Wang R, Wang ZX, Yang JS, Pan X, De W, et al. MicroRNA-451 functions as a tumor suppressor in human non-small cell lung cancer by targeting ras-related protein 14 (RAB14). Oncogene. 2011;30:2644–58.PubMedGoogle Scholar
  199. 199.
    Yin P, Peng R, Peng H, Yao L, Sun Y, et al. MiR-451 suppresses cell proliferation and metastasis in A549 lung cancer cells. Mol Biotechnol. 2015;57:1–11.PubMedGoogle Scholar
  200. 200.
    Fearon DT. The carcinoma-associated fibroblast expressing fibroblast activation protein and escape from immune surveillance. Cancer Immunol Res. 2014;2:187–93.PubMedGoogle Scholar
  201. 201.
    Porter DL, Levine BL, Kalos M, Bagg A, June CH. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med. 2011;365:725–33.PubMedPubMedCentralGoogle Scholar
  202. 202.
    Hodi FS, O’Day SJ, McDermott DF, Weber RW, Sosman JA, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363:711–23.PubMedPubMedCentralGoogle Scholar
  203. 203.
    Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;366:2443–54.PubMedPubMedCentralGoogle Scholar
  204. 204.
    Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med. 2012;366:2455–65.PubMedPubMedCentralGoogle Scholar
  205. 205.
    Byrne KT, Vonderheide RH, Jaffee EM, Armstrong TD. Special conference on tumor immunology and immunotherapy: a new chapter. Cancer Immunol Res. 2015;12:12.Google Scholar
  206. 206.
    Garon EB, Rizvi NA, Hui R, Leighl N, Balmanoukian AS, et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med. 2015;372:2018–28.PubMedGoogle Scholar
  207. 207.
    Rizvi NA, Hellmann MD, Snyder A, Kvistborg P, Makarov V, et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science. 2015;348:124–8.PubMedPubMedCentralGoogle Scholar
  208. 208.
    Brahmer J, Reckamp KL, Baas P, Crino L, Eberhardt WE, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med. 2015;373:123–35.PubMedPubMedCentralGoogle Scholar
  209. 209.
    Carbognin L, Pilotto S, Milella M, Vaccaro V, Brunelli M, et al. Differential activity of nivolumab, pembrolizumab and MPDL3280A according to the tumor expression of programmed death-ligand-1 (PD-L1): sensitivity analysis of trials in melanoma, lung and genitourinary cancers. PLoS One. 2015;10:e0130142.PubMedPubMedCentralGoogle Scholar
  210. 210.
    Hingorani SR, Wang L, Multani AS, Combs C, Deramaudt TB, et al. Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice. Cancer Cell. 2005;7:469–83.PubMedGoogle Scholar
  211. 211.
    Feig C, Jones JO, Kraman M, Wells RJ, Deonarine A, et al. Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer. Proc Natl Acad Sci U S A. 2013;110:20212–7.PubMedPubMedCentralGoogle Scholar
  212. 212.
    Chen Y, Ramjiawan RR, Reiberger T, Ng MR, Hato T, et al. CXCR4 inhibition in tumor microenvironment facilitates anti-programmed death receptor-1 immunotherapy in sorafenib-treated hepatocellular carcinoma in mice. Hepatology. 2015;61:1591–602.PubMedPubMedCentralGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2016

Authors and Affiliations

  • Zhidong Wang
    • 1
  • Jian Sun
    • 2
  • Yeqian Feng
    • 3
  • Xiaocai Tian
    • 4
  • Bin Wang
    • 1
  • Yong Zhou
    • 5
  1. 1.Oncology DepartmentEighth Hospital of ChangshaChangshaChina
  2. 2.Sun Yat-sen University Cancer CenterState Key Laboratory of Oncology in South ChinaGuangzhouChina
  3. 3.Department of OncologyThe Second Xiangya Hospital, Cental South UniversityChangshaChina
  4. 4.Oncology DepartmentHunan Province Geriatric HospitalChangshaChina
  5. 5.The Third Xiangya Hospital of Central South UniversityChangshaPeople’s Republic of China

Personalised recommendations